| Japanese drugmaker Eisai and its American partner, Biogen, said in a news release that the drug, called lecanemab, slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, increasing the therapy's chance of approval as soon as early next year. The companies have already applied to the Food and Drug Administration for accelerated approval for lecanemab based on earlier-stage data. | 
No comments:
Post a Comment